Reviewing Sierra Oncology Inc. (SRRA)’s and OPKO Health Inc. (NASDAQ:OPK)’s results

Since Sierra Oncology Inc. (NASDAQ:SRRA) and OPKO Health Inc. (NASDAQ:OPK) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sierra Oncology Inc. N/A 0.00 49.65M -0.63 0.00
OPKO Health Inc. 990.27M 1.50 153.04M -0.52 0.00

Table 1 demonstrates Sierra Oncology Inc. and OPKO Health Inc.’s top-line revenue, earnings per share and valuation.


Table 2 shows Sierra Oncology Inc. and OPKO Health Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Sierra Oncology Inc. 0.00% -38.9% -36.2%
OPKO Health Inc. -15.45% -16.4% -11.8%

Volatility and Risk

A 1.77 beta indicates that Sierra Oncology Inc. is 77.00% more volatile compared to Standard and Poor’s 500. From a competition point of view, OPKO Health Inc. has a 1.89 beta which is 89.00% more volatile compared to Standard and Poor’s 500.


14.7 and 14.7 are the respective Current Ratio and a Quick Ratio of Sierra Oncology Inc. Its rival OPKO Health Inc.’s Current and Quick Ratios are 0.9 and 0.8 respectively. Sierra Oncology Inc. has a better chance of clearing its pay short and long-term debts than OPKO Health Inc.

Insider and Institutional Ownership

Institutional investors held 67.2% of Sierra Oncology Inc. shares and 24.9% of OPKO Health Inc. shares. Sierra Oncology Inc.’s share held by insiders are 0.1%. Comparatively, 5.7% are OPKO Health Inc.’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sierra Oncology Inc. 13.29% 44.12% 15.98% 12.64% -20.33% 48.48%
OPKO Health Inc. -5.99% -27.45% -22.83% -54.36% -29.74% -11.3%

For the past year Sierra Oncology Inc. has 48.48% stronger performance while OPKO Health Inc. has -11.3% weaker performance.


On 5 of the 9 factors OPKO Health Inc. beats Sierra Oncology Inc.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.